p564569, Author at ISAR Bioscience

By p564569

In

Posted 12. December 2024

Dr. Barbara Krebs-Pohl

By p564569

In

Posted 12. December 2024

Angelika Leppert

By p564569

In News, Start

Posted 11. December 2024

Maria-Elena Torres-Padilla honoured with Leibniz Prize

ISAR Bioscience congratulates Maria-Elena Torres-Padilla, Member of the Board of the Foundation, on winning the Leibniz Prize 2025.

By p564569

In News, Start

Posted 3. December 2024

New member of the foundation’s board of directors

The foundation's board of trustees has appointed Dr. Barbara Krebs-Pohl to succeed Prof. Waldmann on the foundation's board of directors.

By p564569

In Projects

Posted 18. July 2024

Unisens: Groundbreaking technology in receptor research

The UniSens technology is a single-assay platform designed from the ground-up to support the next generation of drug discovery and will enable detection and functional classification of drug [...]

By p564569

In Uncategorized

Posted 18. July 2024

Diseases

Our projects at a glance

By p564569

In News, Start

Posted 5. July 2024

New member of the supervisory board

The foundation's board of trustees has appointed Angelika Leppert as a new member of the Supervisory Board.

By p564569

In News, Start

Posted 10. June 2024

New therapies for autoimmune diseases

ISAR Bioscience convinced a renowned funding agency with the GO-Immun project.

By p564569

In News, Start

Posted 19. February 2024

Regulatory authority gives green light for further development of an Alzheimer’s antibody

The Bavarian research company ISAR Bioscience is well on the way to a new Alzheimer's therapy.

By p564569

In News, Start

Posted 15. December 2023

ISAR Bioscience receives manufacturing authorisation and GMP Certificate

ISAR Bioscience has been granted a manufacturing authorisation in accordance with the German Medicines Act (§13 AMG) and a GMP (Good Manufacturing Practice) certification for its facility in [...]